Introduction
Chemical carcinogenesis is a multistep process characterized in part by gradual loss of controls regulating cell growth and division. Many chemical carcinogens involved in this process are classified as genotoxic agents, which are capable of directly interacting with and disrupting the integrity of genomic DNA. These agents are believed to play a role in the carcinogenic process by causing mutations in key proto-oncogenes or tumor suppressor genes (1) . To date a complete understanding of the cellular components altered as a result of direct or indirect gene mutations by these agents is still lacking. We propose that proteins regulating cell cycle progression represent viable targets that may be altered and involved in the multistep process of genotoxic chemical carcinogenesis.
Normal cell cycle progression is dependent on the activity of serine/threonine kinases known as cyclin-dependent kinases (CDKs) (2) . These kinases associate with a class of proteins called cyclins to form holoenzymes in which the CDK functions as the catalytic domain and the cyclin acts as the regulatory domain (3, 4) . In higher eukaryotes multiple cyclins and CDKs exist. Unique cyclin-CDK partners form at specific times within the cell cycle and are capable of responding to and integrating several types of internal and external signals in order to maintain normal cell cycle progression (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Within the last five years extensive research into the regulation of cyclin-CDK complexes has unveiled a more complex picture of the holoenzymes and the biochemical pathways that converge upon them. Work conducted by Xiong et al. (13) showed that in human fibroblasts cyclin-CDKs exist as quaternary complexes composed of a cyclin, its CDK partner, proliferating cell nuclear antigen (PCNA) and p21 WAF1 . PCNA, a well-characterized molecule that serves as an auxiliary protein to DNA polymerase δ functions as a DNA replication and repair factor (14) . The associating 21 kDa protein has since been found to be a universal inhibitor of CDKs (15) (16) (17) that can be transcriptionally activated by the p53 gene product (18) (19) (20) . Numerous CDK inhibitors (CDIs) have been discovered since the finding of p21 WAF1 (21) (22) (23) (24) (25) . These CDIs have been categorized into two families: the p21 family and the p16 family. Members of the p21 family include p21 WAF1 , p27 KIP1 (26, 27) and p57 KIP2 (28, 29) . These proteins bind to cyclin-CDK complexes and inhibit kinase activity in vitro. Overexpression of these molecules in vivo leads to G1 arrest. The p16 family members p15 INK4b (30) , p16 INK4a (31, 32) , p18 INK4c (33) and p19 INK4d (34) preferentially bind to CDK4 or CDK6 to form binary complexes. They function in part to sequester these CDKs and prevent formation of active G1 cyclin D 1 -CDK protein complexes.
Analyses of quaternary complexes in virally transformed human fibroblasts and epithelial cells revealed that these holoenzymes are disrupted or rearranged after transformation (35) . Cyclin D 1 -CDK4-p21 WAF1 -PCNA complexes are rearranged and replaced with a CDK4-p16 INK4a binary complex. p21 WAF1 and PCNA completely dissociate from other quaternary complexes, leaving binary complexes of cyclin A-CDK2 and cyclin B 1 -CDC2 intact. Subsequent studies showed that expression of specific viral oncoproteins (SV40 T antigen or HPV E6 and E7) can inactivate the tumor suppressor gene products p53 and retinoblastoma protein (pRb) and lead to similar changes in quaternary complexes prior to neoplastic transformation of normal human fibroblasts (36, 37) . These findings suggest that perturbations in biochemical pathways regulating formation of CDK protein complexes may play a causal role in cellular transformation by inducing dysregulated cell cycle progression and genomic instability.
Currently little is known about the cellular components that can be altered as a consequence of genetic mutations caused by genotoxic chemical carcinogens. Therefore, the present study was conducted to investigate whether transformation of cells by 3-methylcholanthrene (MC) and N-methyl-NЈ-nitro-N-nitrosoguanidine (MNNG) can lead to alterations in formation of CDK protein complexes. We focused on investigating changes in cyclin D 1 -CDK protein complexes since these holoenzymes play an important role in integrating growth factor pathways with progression into the cell cycle (4) . We also chose to use mouse liver cells in our study since this cell type is the most common target in rodents for chemical carcinogenesis (38) , and a significant amount of research has been conducted on chemically induced hepatocarcinogenesis. Initial studies involved characterizing D 1 -type CDK protein complexes in a non-tumorigenic mouse liver cell line (BNL CL.2). We found that cyclin D 1 associated with CDK6, CDK4 or CDK2 to form several types of cyclin D 1 -CDK-CDI protein complexes. After transformation of the BNL CL.2 mouse liver cell line with either MC or MNNG we observed that the composition of select cyclin D 1 -CDK-CDI protein complexes was altered, and in some cases kinase activity was affected.
Materials and methods

Cell culture
A mouse liver cell line (BNL CL.2) established from BALB/c embryonic liver cells was purchased from the American Type Culture Collection (ATCC, Rockville, MD) and used for characterization of CDK protein complexes. 3-Methylcholanthrene epoxide-transformed (BNL 1ME A.7R.1), MNNGtransformed (BNL 1NG A.2) and SV40-transformed (BNL SV A.8) liver cells, all of which were derived from BNL CL.2 cells, were also available from ATCC and used to assess changes in CDK protein complexes after chemical and viral transformation. All four cell lines were established and characterized by Patek et al. (38) . The BNL CL.2 cells are immortalized mouse liver cells which show no tumor cell phenotype, as measured by anchorage-independent growth and in vivo tumorigenicity. MC-, MNNG-and SV40-transformed liver cells, however, are capable of growing in soft agar and forming tumors in immunodeficient mice (39, 40) . All cell lines were grown at 37°C in 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 0.3% nystatin (Gibco BRL). 35 S cell labeling mix, sp. act. Ͼ1000 Ci/ml; Amersham) was added directly to the medium (final concentratioñ 200 µCi/ml). Cells were incubated at 37°C for 4 h in a sealed plexiglass chamber. After labeling, plates were placed on ice, the medium was removed and the cells were washed three times with cold phosphate-buffered saline (PBS). Lysis buffer [50 mM Tris base, pH 7.4, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 2 VO 3 , 1 mM dithiolthreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml leupeptin, 10 µg/ml aprotinin and 2 µg/ml pepstatin A] was added (1 ml/100 mm plate) for 30 min to release cellular proteins. Lysates were collected and spun at 15 000 g for 15 min to remove cellular debris. Lysates were precleared for 2 h using normal rabbit serum (Vector Laboratories Inc., Burlingame, CA) adsorbed onto protein A-agarose beads (Sigma). Beads were pelleted by centrifugation (500 g), supernatants were collected and concentration of protein in the lysates was determined (BioRad Bradford Assay). Two milligrams of protein lysate were incubated with primary antibody for 2 h to overnight at 4°C. ImmunoPure immobilized protein A-agarose beads (Pierce Chemical Co., Rockford, IL) were added to immunoprecipitation reactions to adsorb the antigen-antibody complexes. After a 1 h incubation immunoprecipitates were collected by centrifugation (500 g) and washed four times (50 mM Tris base, pH 7.4, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 2 VO 3 , 1 mM DTT and 1 mM PMSF). Antigen-antibody complexes were dissociated by resuspending beads in SDS sample buffer (2.5% SDS, 25% glycerol, 25 mM Tris base, pH 8.0, 2.5 mM EDTA, 0.1 M DTT and pyronin Y). Samples were boiled at 100°C for 3 min and separated on 17.5% SDS-polyacrylamide gels. Gels containing radiolabeled proteins were fixed for 30 min (10% glacial acetic acid and 25% isopropanol) then enhanced for 30 min with a fluorographic reagent (Amplify; Amersham Life Science Inc., Arlington Heights, IL). Gels were dried and exposed to Hyperfilm-MP (Amersham) at -80°C.
To verify the identity of bands visualized from the [ 35 S]methionine-labeled immunoprecipitates, reactions were performed without radiolabeling the proteins. These precipitates were also separated on a 17.5% SDS-polyacrylamide gel but then transferred to a polyvinyl membrane (PVDF, Immobilon-P; Millipore) for Western blotting. Transfer of proteins to a polyvinyl membrane was achieved using a BioRad Trans-Blot Cell. PVDF membranes were blocked for 1 h to overnight with 5% non-fat dry milk in PBS containing 0.1% Tween 20. After blocking membranes were washed with PBS/Tween 20 (PBS-T) then incubated with primary antibody (0.1-1 µg/ml primary antibody diluted in PBS-T) for 1 h to overnight. Membranes were washed and exposed to the appropriate secondary antibody (1:10 000 dilution of either sheep anti-mouse or donkey anti-rabbit immunoglobulin coupled to horseradish peroxidase; Amersham). Specific proteins were detected using an enhanced chemiluminescence system from Amersham. At least three independent experiments were conducted for all radiolabeled immunoprecipitation reactions and immunoprecipitations coupled with Western blotting. Almost identical results were produced each time. CDK6/CDK4 kinase assay Subconfluent cells in culture (60-80%) were rinsed three times with cold PBS while on ice. Kinase assay lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween 20, 10% glycerol, 10 mM β-glycerophosphate, 1 mM NaF, 0.1 mM Na 2 VO 3 , 1 mM DTT, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin and 2 µg/ml pepstatin A) was added directly to the plates (2 ml/150 mm dish). Cells were then scraped, transferred to a chilled microfuge tube and frozen immediately in liquid nitrogen. Frozen lysates were thawed and placed on ice for 2 h. Samples were spun for 15 min at 15 000 g to pellet cellular debris and chromosomal DNA. Supernatants were removed and incubated with protein A beads (Sigma). After samples were rotated for 1 h at 4°C, they were spun for 3 min at 500 g to pellet the beads. Supernatants were collected and protein concentrations were determined (Pierce BCA Protein Assay). To immunoprecipitate CDK6 or CDK4 protein complexes from collected cellular lysates 500 µg protein were incubated overnight at 4°C with 2 µg of either anti-CDK6 or anti-CDK4 rabbit polyclonal antibodies. ImmunoPure immobilized protein A-agarose beads (Pierce Chemical Co., Rockford, IL) were added to immunoprecipitation reactions to adsorb the antigen-antibody complexes. After a 1 h incubation immunoprecipitates were collected by centrifugation (500 g) and washed three times in kinase assay lysis buffer, then once in kinase assay reaction buffer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 and 1 mM DTT). After removing the final wash, 12 µl kinase reaction mix (5 µCi [γ-32 P]ATP, 10 µM ATP and 1 µg GST-pRb; a gift from Onyx Pharmaceuticals, Richmond, CA) were added to each tube. Samples were mixed briefly then spun gently before incubating the tubes at 30°C for 30 min. Kinase reactions were terminated by addition of SDS sample buffer. Samples were boiled for 5 min, cooled, then loaded onto a 15% SDS-polyacrylamide gel. Gels were dried for 1.5 h at 80°C then exposed to a phosphor screen (Molecular Dynamics). Images were quantitated using ImageQuant v.3.3 (Molecular Dynamics). At least three independent experiments were conducted to assess kinase activity of CDK6 and CDK4. A two-tailed paired Student's t-test was conducted to determine whether the mean kinase activity for chemically and virally transformed liver cells differed from the mean values obtained for the non-tumorigenic liver cell line BNL CL.2.
Mouse p53 gene sequencing Total RNA was isolated from BNL CL.2, BNL 1ME A.7R.1 and BNL 1NG A.2 liver cell lines using the RNAzol™ B method. Reverse transcription reactions were performed using Superscript™ II reverse transcriptase (Gibco BRL) and followed the manufacturer's instructions. One microliter of the cDNA reaction was used as template to amplify p53 cDNA in PCR. Reactions consisted of 50 pmol each MC01 and MC02 primers, described in Sun et al. (40) , PCR buffer (Perkin Elmer), 200 µM each dNTP (Gibco BRL) and 1.25 U AmpliTaq ® DNA polymerase (Perkin Elmer). The PCR reaction was heated to 94°C for 2 min before 30 cycles of melting (94°C for 1 min), annealing (60°C for 1 min) and extension (72°C for 45 s) were completed. A final incubation at 60°C for 7 min was performed to complete any extensions. The PCR reaction yielded a 1246 bp fragment that flanked the entire coding region of the p53 cDNA. PCR reactions were spun through Centricon-100 concentrator columns (Perkin Elmer) to remove primers. Two microliters of the purified and concentrated fragment were then used in a cycle sequencing reaction using the ABI PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit. The following primers were used in separate cycle sequencing reactions for each cell line: MC01, MC02, MC08, MC03, MC04, MC05 and MC06 (see 40 for primer sequences). Cycle sequencing reactions were carried out on a Perkin Elmer Cetus GeneAmp PCR System 9600. Each reaction generated a fragment that was purified by ethanol precipitation and resuspended in loading buffer (50 mM EDTA). Samples were run on an ABI 373 DNA Sequencer. Data were analyzed using Factura and Autoassembler (Applied Biosystems Divisions).
Population doubling times and percentage in S phase determinations
Population doubling times were determined by plating 2ϫ10 4 cells/100 mm culture dish. Every 24 h cells were trypsinized and counted using a hemocytometer. Values were plotted over time (5 days), and population doubling times were calculated using the portion of the curve representing log phase growth.
The percentage of cells in S phase was determined using the flow cytometric techniques described in White et al. (41) . Newly synthesized DNA was labeled in log phase growing cells with 10 µM bromodeoxyuridine (BrdU; Sigma) for 3 h prior to fixation in PBS:ethanol (1:2 v/v). Nuclei were then isolated by pepsin digestion. Incorporated BrdU was detected using an antiBrdU-fluorescein isothiocynate conjugated antibody (Becton Dickinson), and total DNA was stained with 50 µg/ml propidium iodide. Cell cycle analysis was performed using a Becton Dickinson FACS Vantage instrument. Data were acquired and analyzed using Lysis II software (Becton Dickinson). Percentage of cells in G1 or G2 could not be determined due to the presence of diploid and tetraploid populations in the mouse liver cell lines. A twotailed paired Student's t-test was conducted to determine whether the mean population doubling time and proportion in S phase for chemically and virally transformed liver cells differed from the mean values obtained for the nontumorigenic liver cell line BNL CL.2.
Results
Characterization of D 1 -type CDK complexes in non-tumorigenic mouse liver cells
Since little is known about the composition of CDK protein complexes in mouse liver cells, initial studies involved characterizing these complexes in the non-tumorigenic mouse liver cell line BNL CL.2. The results discussed below were reproduced in three independent experiments. CDK6 was present in binary and tertiary complexes. To characterize CDK6 complexes in non-tumorigenic mouse liver cells, an anti-CDK6 polyclonal antibody was used to immuno- Figure 1A and B). Interestingly, CDK6-associating p27 KIP1 detected by Western blotting had been found at times to migrate with a mass of 27 kDa and at other times with a molecular weight of 31 kDa, the latter being consistent with that observed in radiolabeled anti-CDK6 immunoprecipitates. This observation suggests that CDK6-associating p27 KIP1 may be post-translationally modified in proliferating cells.
To determine whether cyclin D 1 , CDK6, p27 KIP1 and p15 INK4b proteins associated as one protein complex reciprocal, 35 Slabeled immunoprecipitations were performed using either an anti-cyclin D 1 or anti-p27 KIP1 rabbit polyclonal antibody. In both precipitates proteins migrating with molecular weights of 38, 36 and 27 kDa were detected along with additional bands that will be discussed later ( Figure 1A, lanes 1 and 6) Figure  1A, lane 3) . Non-radiolabeled immunoprecipitations followed by Western blotting confirmed that these proteins were p36cy-clin D 1 , p33CDK4, p27 KIP1 , p21 WAF1 and p15 INK4b , respectively ( Figure 1B, lane 3) . PCNA was also detected by Western blotting in anti-CDK4 immunoprecipitates ( Figure 1B, lane  3) , but the protein was difficult to visualize in radiolabeled immunoprecipitates.
To determine whether all five proteins coexisted as one complex, reciprocal radiolabeled and non-radiolabeled immunoprecipitations were carried out with anti-cyclin D, anti-p21 WAF1 and anti-p27 KIP1 rabbit polyclonal antibodies. Anti-cyclin D precipitates contained PCNA (visualized only in Figure 1B, lane 1) , cyclin D 1 , CDK4, p27 KIP1 and p21 WAF1 , but not p15 INK4b ( Figure 1A and B, lanes 1). Anti-p21 WAF1 coprecipitated PCNA (visualized only in Figure 1B , lane 5), cyclin D 1 , CDK4 and p21 WAF1 , but not p27 KIP1 or p15 INK4b ( Figure 1A and B, lanes 5). Anti-p27 KIP1 antibody recovered cyclin D 1 , CDK4 and p27 KIP1 , but not PCNA, p21 WAF1 or p15 INK4b ( Figure 1A and B, lanes 6). Dissection of these results revealed that p27 KIP1 and p21 WAF1 existed in separate CDK complexes, since they did not coexist in anti-p27 KIP1 or antip21 WAF1 precipitates. In addition, since none of the antibodies recovered p15 INK4b ( Figure 1A and B, lanes 1, 5 and 6 Figure 1B, lane 2) . Most of these proteins (with the exception of PCNA) could also be easily visualized in 35 S-labeled anti-CDK2 precipitates ( Figure 1A , lane 2).
Reciprocal immunoprecipitations using anti-cyclin D, antip21 WAF1 and anti-p27 KIP1 were performed to determine whether all of the proteins existed in one complex. Protein complexes isolated with anti-cyclin D looked similar to the anti-CDK2 precipitates in that they both recovered p40PCNA (visualized in Figure 1B , lane 1 only), p36cyclin D 1 , p32CDK2, p27 KIP1 and p21 WAF1 ( Figure 1A and B, lanes 1) . Anti-p21 WAF1 precipitates contained PCNA (seen in Figure 1B , lane 5 only), cyclin D 1 , CDK2 and p21 WAF1 , but not p27 KIP1 ( Figure 1A and B, lanes 5). Anti-p27 KIP1 pulled down cyclin D 1 , CDK2 and p27 KIP1 , but not p21 WAF1 or PCNA ( Figure 1A and B, lanes 6). Again, p27 KIP1 and p21 WAF1 appeared to exist in separate complexes since they did not co-precipitate with each other in anti-p27 KIP1 or anti-p21 WAF1 precipitates. From these data several types of complexes emerged: CDK2 could associate with cyclin D 1 to form binary (cyclin D 1 -CDK2), tertiary (cyclin D 1 -CDK2-p27 KIP1 ) or quaternary (cyclin D 1 -CDK2-p21 WAF1 -PCNA) complexes. (Figure 3) . As was the case with CDK6, CDK4 protein levels remained consistent between cell lines (Figure 3, row 1) . However, recovery of CDK4-associating cyclin D 1 was reduced relative to the control in MC-transformed cells (Figure 3, row 3 ). In the same cell line CDK4-associating PCNA and p21 WAF1 were significantly decreased, but p27 KIP1 levels remained similar to control levels ( protein levels were slightly elevated in the chemically and virally transformed cells relative to the BNL CL.2 control cells ( Figure 4, row 1) , whereas CDK2-associating PCNA, cyclin D 1 and p21 WAF1 were significantly decreased in all tumorigenic cell lines ( Figure 4 , rows 2, 3 and 5 respectively). Interestingly, p27 KIP1 levels in association with CDK2 were significantly increased in the MC-and SV40-transformed cells (Figure 4, row 4) . In summary, formation of binary (cyclin D1-CDK2), tertiary (cyclin D 1 -CDK2-p27 KIP1 ) and quaternary (cyclin D 1 -CDK2-p21 WAF1 -PCNA) complexes were decreased after chemical and viral transformation of mouse liver cells. Changes in total cellular protein levels of cyclin D 1 , p21 WAF1 and PCNA in chemically transformed mouse liver cells Total cellular levels of cyclin D 1 , p27 KIP1 , p21 WAF1 and PCNA proteins were evaluated in the non-tumorigenic and tumorigenic mouse liver cell lines by immunoprecipitating and immunoblotting techniques to determine whether the decreased formation of cyclin D 1 -CDK protein complexes was due in part to changes in total cellular levels of CDK-associating proteins. Total cellular levels of cyclin D 1 protein were decreased in MC-and SV40-transformed cell lines, however, they remained unchanged in MNNG-transformed liver cells ( Figure 5, row 2) . Total cellular levels of p21 WAF1 were also decreased in the MC-, MNNG-and SV40-transformed mouse liver cells as compared with the non-tumorigenic BNL CL.2 cell line ( Figure 5, row 4) . Interestingly, total cellular levels of p27 KIP1 protein remained unaltered in the chemically transformed mouse liver cell lines but was slightly decreased in SV40-transformed cells ( Figure 5, row 4) . Furthermore, cellular levels of PCNA protein were elevated in all tumorigenic cell lines relative to BNL CL.2 mouse liver cells ( Figure 5, row 1) .
Alteration of cyclin D 1 -CDK4 protein complexes in chemically transformed mouse liver cells. Detection and comparison of CDK4 protein complexes were achieved by immunoprecipitating and immunoblotting reactions
Sequencing of the mouse p53 gene
To determine whether mutations in the p53 gene contributed to the observed changes in cellular levels of p21 WAF1 , seven separate fragments of p53 cDNA that overlapped one another and spanned the entire coding region were sequenced. No mutations in the p53 gene were observed in the non-tumorigenic control or in the MC-or MNNG-transformed tumorigenic liver cells. non-tumorigenic BNL CL.2 control cells. Results showed that the amount of p15 INK4b protein in association with CDK6 was decreased in the chemically (and virally) transformed mouse liver cell lines as compared with their non-tumorigenic counterpart ( Figure 6 ). p15 INK4b protein was also decreased in association with CDK4 in the MNNG-and SV40-transformed mouse liver cells but was slightly elevated in MC-transformed cells.
Alteration of CDK protein kinase activity after chemical transformation of mouse liver cells
Kinase activity of CDK6 and CDK4 protein complexes was evaluated in the non-tumorigenic and tumorigenic mouse liver cell lines to determine whether decreased formation of cyclin D 1 -CDK protein complexes resulted in decreased function of the CDKs. CDK2 activity was not evaluated since this kinase can be activated by association with non-D-type cyclins, such as cyclin E and cyclin A. Specifically, CDK6 and CDK4 protein complexes were isolated using immunoprecipitating techniques. Kinase activity was measured by assessing the ability of the CDK to phosphorylate a portion of pRb. Results indicated that CDK6-associated kinase activity was elevated 2.7-fold in the MC-transformed mouse liver cell, whereas activity in MNNG-transformed cells remained similar to the control ( Figure 7 and Table I ). CDK4-associated kinase activity was decreased in MC-transformed cells by 58%, but remained unchanged in MNNG-transformed mouse liver cells ( Figure 7 and Table I (Figure 8) . Specifically, cyclin D 3 protein was elevated in the MC-transformed mouse liver cell line relative to the non-tumorigenic control, whereas levels found in MNNG-and SV40-transformed cells did not differ dramatically from the BNL CL.2 control.
The amount of cyclin D 3 associating with the CDKs was also evaluated. Although cyclin D 3 did not bind to CDK2 (data not shown), increased levels were found in association with CDK6 and CDK4 within the MC-transformed mouse liver cell line as compared with the non-tumorigenic control cell line. Levels of cyclin D 3 -CDK protein complexes did not appear to be altered in the MNNG-or SV40-transformed cells (Figure 8 ). Thus in at least the MC-transformed cell line, cyclin D 3 -CDK protein complexes appeared to be elevated relative to the control cell line.
Population doubling times and percent of cells in S phase
Population doubling times were calculated for each cell line during log phase growth. The percentage of cells in S phase was determined for each cell line at the time lysates were collected for isolation of CDK protein complexes. Results are listed in Table II . No significant difference in population doubling time was observed between the immortalized and chemically transformed cell lines. However, the virally transformed cells exhibited a significantly shorter population doubling time relative to the non-tumorigenic control. Interestingly, the percentage of cells in S phase was significantly greater in the chemically transformed liver cells compared with the non-tumorigenic counterpart, but no difference was observed between control and virally transformed liver cells.
Discussion
The present study was undertaken to determine whether transformation of mouse liver cells by the genotoxic carcinogens MC and MNNG could lead to alterations in the cyclin D 1 -CDK-CDI protein complexes, which play an important role in integrating external growth signals with cell cycle progression through G1.
In the non-tumorigenic immortalized mouse liver cell line BNL CL. Figure 9 ). In addition, distinct changes in cyclin D 1 -CDK-CDI holoenzymes existed among the chemically and virally transformed mouse liver cell lines, suggesting that each line harbored unique mutations or alterations that differentially D-type cyclins play an integral role in transducing growth factor stimuli to the cell cycle machinery. Therefore, aberrant levels of D-type cyclins may provide a growth advantage over normal cells by allowing proliferation to occur under suboptimal conditions or by causing cells to become resistant to negative growth signals. Uncontrolled cell cycle progression, a key phenotypic change associated with tumorigenicity, could lead to genomic instability and accelerate neoplastic progression.
In our study we specifically observed a decrease in formation of cyclin D 1 -CDK4 protein complexes in MC (and SV40)-transformed cells. These changes translated into decreased activity of the CDK4 enzyme, suggesting that CDK4 kinase activity was predominantly modulated by cyclin D 1 binding in these cells. Thus MC (and SV40)-transformed mouse liver cells appeared to have evolved a mechanism to decrease their dependence on functional cyclin D 1 -CDK protein complexes. Interestingly, CDK6 activity was elevated 2.7-fold in MCtransformed cells, despite significant disruption of cyclin D 1 -CDK6 protein complexes. We later found that cyclin D 3 protein levels were dramatically elevated in MC-transformed cells relative to the control cell line and that this cyclin associated significantly with CDK6. Thus transforming events in the MC-transformed cell line resulted in decreased cyclin D 1 protein levels, but aberrant levels of cyclin D 3 and significant formation of active cyclin D 3 -CDK6 protein complexes.
Cyclin D-CDK6 or -CDK4 protein complexes have been shown to possess a distinct substrate specificity for pRb (10, 42, 43) . Alterations in these holoenzymes may therefore affect the activity of pRb tumor suppressor protein, which controls transition into S phase and regulates transcription of genes needed for DNA synthesis (10 The role of cyclin D 1 -CDK2 protein complexes is not as well defined. They have been detected in the Yi1 protein complex that binds to the mouse thymidine kinase gene (TK) promoter during early G1 (44) . The Yi1 complex appears to regulate TK gene expression, which is tightly coupled with the onset of S phase (45, 46) . Altered cyclin D 1 -CDK2-CDI protein complexes after chemical (or viral) transformation could affect transcription of specific genes (such as TK) needed for DNA synthesis and normal S phase progression. Interestingly, it appeared that the MC-and MNNG-transformed liver cells were spending more time in S phase relative to the non-tumorigenic control, which may have been due to premature entry into S phase or delayed S phase progression. Alterations in the cyclin D 1 -CDK-CDI protein complexes may have contributed to the observed changes in cell cycle kinetics.
Characterization of cyclin D-CDK-CDI protein complexes in mouse liver cell lines also led to the detection of several negative regulators of cell proliferation, namely p27 KIP1 , p21 WAF1 and p15 INK4b . These proteins were found in association with various CDKs and have been shown to affect stability and activity of cyclin D-CDK protein complexes (30) (31) (32) (33) (34) 47) . These CDIs are likely to play an important role in controlling cell cycle progression within mouse liver cells, and biochemical pathways regulating expression of these proteins may represent additional pathways vulnerable to attack during chemical transformation of mouse liver cells.
In our studies we found that cellular levels of p21 WAF1 were decreased after chemical and viral transformation, possibly contributing to the observed changes in quaternary (cyclin D 1 -CDK-p21 WAF1 -PCNA) complexes within these cell lines. The p53 tumor suppressor protein has been shown to transcriptionally activate p21 WAF1 (48) , and p21 WAF1 is believed to stabilize the quaternary complexes when present at low levels (47) . Sequencing of the p53 gene, however, revealed that the p53 gene was not mutated in either of the chemically transformed cell lines. These findings suggest that other genetic alterations may be responsible for lowering p21 WAF1 protein levels within the chemically transformed cell lines. The dramatic decrease in p21 WAF1 protein levels and disruption of quaternary (cyclin D 1 -CDK-p21 WAF1 -PCNA) protein complexes in SV40-transformed liver cells were likely due to the presence of large T antigen, which is capable of binding to and inactivating p53 (49) .
We also evaluated levels of p16-type CDK inhibitors in association with CDK6 or CDK4, since these proteins can compete with cyclin D for binding with CDK6 or CDK4 and prevent formation of active D-type CDK protein complexes (30) (31) (32) (33) (34) . In the mouse liver cell lines used in our studies only p15 INK4b could be detected. Levels of p15 INK4b in association with CDK6 were dramatically decreased in the chemically and virally transformed cell lines, implying that disruption of cyclin D 1 -CDK6-CDI protein complexes was not due to increased association of CDK6 with p15 INK4b . Instead, the dramatic disruption of cyclin D 1 -CDK6-CDI complexes observed in the MC-transformed cells was likely due to overexpression of cyclin D 3 (as discussed previously), which led to increased association of cyclin D 3 with CDK6 and abundant kinase activity of the CDK6 enzyme. Alternatively, p15 INK4b levels were elevated in association with CDK4 in MC-transformed mouse liver cells, correlating with decreased formation and activation of cyclin D1-CDK4 protein complexes in this cell line.
Some of the cell cycle protein complexes did not change after chemical transformation. Quaternary (cyclin D 1 -CDK4-p21 WAF1 -PCNA) complexes isolated from MNNG-transformed liver cells remained intact, and the amount recovered from this transformed cell line was similar to that seen with the non-tumorigenic control. In addition, tertiary (cyclin D 1 -CDK4-p27 KIP1 ) complexes isolated from both the MC-and MNNG-transformed cell lines remained unchanged (data not shown). Some investigators have hypothesized that all human tumors and tumorigenic cell lines are likely to possess disrupted cyclin D 1 -CDK4-CDI protein complexes (35) . Our studies showed that this effect does not always occur after cellular transformation, suggesting that the transformation process in rodent and human cells may involve different molecular changes or that disruption of cyclin D 1 -CDK4-CDI protein complexes may not be obligatory for all cases of chemical transformation.
In summary, our study characterized D-type CDK protein complexes in mouse liver cells and provided the first example that these complexes, which function to integrate growth factor pathways with cell cycle progression, can be altered physically and functionally after chemical transformation with the genotoxic carcinogens MC and MNNG. These complexes were differentially altered among the MC-, MNNG-and SV40-transformed liver cells, suggesting that each cell line may have harbored distinct molecular alterations that contributed to the rearrangement of cyclin D 1 -CDK-CDI protein complexes. Although MC and MNNG are not likely to mutate the same gene each time during chemical transformation, this study demonstrates that components of the cell cycle machinery have the potential of being targeted and altered during genotoxic chemical carcinogenesis. Identifying cellular and molecular targets involved in genotoxic chemical carcinogenesis is an important first step toward providing a biological basis for phenotypic changes observed after chemical transformation of mouse liver cells.
